Wikipedia
Odanacatib
Odanacatib ( pINN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis. It is an inhibitor of cathepsin K, an enzyme involved in bone resorption.
It is being developed by Merck & Co.. The phase III clinical trial for this compound was stopped early after a review showed it was highly effective and had a good safety profile. Merck announced in 2014 that it would apply for regulatory approval in 2015, but as of early 2016 there was no report of any application. In 2014 Cowen and Co predicted odanacatib will generate a billion USD per year in sales by 2020.
This drug was developed at Merck Frosst in Montreal.